Trial Profile
Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 14 Aug 2015
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 24 May 2011 Actual initiation date (Jan 2011) added as reported by ClinicalTrials.gov.
- 24 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 08 Sep 2010 New trial record